Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PABPC1 | P11940 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Temozolomide SCHEMBL3270220 | 1.00 | MEN1 (1.00) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL4746638 | 0.98 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3784250 | 0.98 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL28275477 | 0.98 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL1534013 | 0.98 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL27721442 | 0.94 | MEN1 (0.89) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL16227379 | 0.91 | MEN1 (0.82) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL10168201 | 0.90 | MEN1 (0.81) | MEN1PABPC1KMT2ACA12CA1 | |
| Altretamine SCHEMBL27875070 | 0.89 | KMT2A (0.80) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL4444959 | 0.88 | MEN1 (0.78) | MEN1PABPC1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 109504 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144750-A1 | Dosing Regimens for Treatment of Glioblastoma | SIGNPATH PHARMA INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4747388-A1 | RECOMBINANT BACTERIAL CELL CAPABLE OF EXPRESSING A HETEROLOGOUS EXTRACELLULAR MATRIX (ECM) DEGRADING POLYPEPTIDE USING A TUMOUR-INDUCIBLE PROMOTER | NEOBE THERAPEUTICS LTD (GB) | 2026-05-27 | — | — | EP | claimed |
| US-12637545-B2 | Polymers for gene therapy | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2026-05-26 | — | — | US | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| CN-122074048-A | Methods of treating cancer | 诺华股份有限公司 | 2026-05-22 | — | — | CN | claimed |
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260139071-A1 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | JANSSEN BIOTECH INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137700-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| CN-1145622-A | O 6Substituted guanine derivatives, process for their preparation and their use | CANCER RES CAMPAIGN TECH (GB) | 1997-03-19 | — | — | CN | claimed |
| WO-1997007804-A1 | COMBINATION THERAPY FOR ADVANCED CANCER COMPRISING TEMOZOLOMIDE AND CISPLATIN | SCHERING CORPORATION (US) | 1997-03-06 | — | — | WO | claimed |
| EP-0702683-A1 | 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-03-27 | — | — | EP | claimed |
| CN-1117711-A | Synergistic method of temozolomide for treating human tumor cells | CANCER RES CAMPAIGN TECH (GB) | 1996-02-28 | — | — | CN | claimed |
| EP-0679086-A1 | POTENTIATION OF TEMOZOLOMIDE IN HUMAN TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-11-02 | — | — | EP | claimed |
| WO-1994029312-A1 | O6-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1994-12-22 | — | — | WO | claimed |
| WO-1994015615-A1 | POTENTIATION OF TEMOZOLOMIDE IN HUMAN TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY, LTD. (GB) | 1994-07-21 | — | — | WO | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| US-5260291-A | Tetrazine derivatives | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-11-09 | — | — | US | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |